Wilson's disease is an autosomal recessive trait, which means that the patient must have inherited one copy of the defective gene from each parent in order to be affected. If a patient only has one faulty gene, he or she will not become ill, but will be a carrier and can pass the gene on to their children. Wilson's disease symptoms typically appear between the ages of 12 and 23, according to National Library of Medicine data, and untreated patients can live for up to 40 years. On the other hand, early detection and treatment of Wilson's disease may help people live longer lives. Because copper is not properly eliminated in Wilson's disease, it accumulates in the body above normal levels. Wilson's disease symptoms are most common between the ages of 12 and 23. Symptoms include swelling, fatigue, stomach pain, and uncontrolled or poorly coordinated motions.
Furthermore, medications such as D-Penicillamine and Trientine are frequently used in treatment because they cause the organs, typically the liver, to release extra copper into the bile, which carries copper, waste products, and toxins to the digestive tract and excrete. Once in the bloodstream, it can be removed from the body via the kidneys. Wilson's disease is caused by disruptions or changes (mutations) in the ATP7B gene, which is involved in the transfer of excess copper from the liver to the bile, where it is eventually excreted from the body via the intestines.
The global Wilson's Disease Treatment Market is expected to be worth US$ 527.0 million in 2022, with a CAGR of 6.2% during the forecast period (2022-2030).
Leading Companies in the Wilson's Disease Treatment Industry:
1. Valeant Pharmaceuticals International, Inc.
Bausch Health Companies Inc. is a multinational specialty pharmaceutical company headquartered in Laval, Quebec. It creates, manufactures, and sells branded generic drugs and pharmaceutical products, primarily for skin diseases, gastrointestinal disorders, eye health, and neurology.
Syprine, which treats Wilson disease, gained notoriety after Valeant Pharmaceuticals International raised the drug's price to $21,267 in 2015, up from $652 just five years before.
2. Noblepharma Co., Ltd.
Nobel Pharma Co.,Ltd was established in 2003. The Company's primary business is commercial physical and biological research and development.
Nobelpharma is a small Japanese pharmaceutical company dedicated to developing treatments for rare diseases. Small pharma employs a novel approach to treating neglected diseases.
3. Wilson Therapeutics AB
Wilson Therapeutics, based in Stockholm, Sweden, is a biopharmaceutical company that develops novel therapies for patients suffering from rare copper-mediated disorders.
The lead product of Wilson Therapeutics, WTX101, is in Phase 3 development as a novel treatment for Wilson Disease. Wilson Therapeutics is traded on Nasdaq Stockholm under the ticker WTX in the Mid Cap segment.
4. Kadmon Holdings, Inc.
Kadmon is a biopharmaceutical company that creates novel products to address significant unmet medical needs. Their pipeline of products focuses on inflammatory and fibrotic diseases, as well as immuno-oncology.
Kadmon announces FDA approval of generic trientine hydrochloride in 2019. By 2030, the global market for Wilson's disease treatment will have surpassed US$ 854.5 million.
5. Merck & Co., Inc.
Merck & Co., Inc. is named after the Merck Group, which was founded in Germany in 1668 and was once the American arm of the Merck Group. Outside of the United States and Canada, the company is known as Merck Sharp & Dohme, or MSD.
The FDA requested Merck's Cuprid orphan drug for Wilson's disease.
6. VHB Life Science Ltd.
VHB Life Sciences Limited is a pharmaceutical firm. Antibacterial, infective, hemolytic, fungal, poisoning, oxidant, thrombotic, anasthetic, cough syrup, calciym, cardiac injection, gonadotropins, gynaecology, and nephro drugs are available from the company. VHB Life Sciences has customers all over the world.
The National Pharmaceutical Pricing Authority (NPPA) has requested that VHB Life Science Ltd. ensure the market availability of Penicillamine, which is used to treat Wilson's disease.
7. Teva Pharmaceuticals USA, Inc.
Teva Pharmaceuticals has been developing and manufacturing medicines to help people live better lives for over a century. With a portfolio of 3,500 products in nearly every therapeutic area, we are committed to being a global leader in generic and specialty medicines.
Teva Pharmaceutical Industries Ltd. announced today the availability of generic Syprine1 (trientine hydrochloride) capsules in the United States.
Trientine hydrochloride is used to treat Wilson's disease patients who are intolerant to penicillamine.
8. Tsumura & Co.
Tsumura & Co. (Tsumura) is a traditional pharmaceutical company that sells Kampo extract intermediates and granular Kampo formulations. The company's product portfolio includes prescription Kampo products, over-the-counter (OTC) Kampo formulations, crude drug pieces, and crude drug raw materials.
Wilsons Disease Treatment Market Innovative Treatments, Success Milestones by Tsumura and Forecasts by 2026.
*Definition: Wilson's disease is a rare inherited disorder in which copper accumulates in the liver, brain, and other vital organs.
